Satellos Bioscience Inc · TSX:MSCL
Satellos Bioscience — Investor Presentation (February 2022)
21 slides from Satellos Bioscience's investor presentation, Feb 22, 2022
Slide 1: Satellos Bioscience Inc.
Feb 22, 2022 SATELLOS BIOSCIENCE INC. Rebuilding muscle from within TM TSX: MSCL.V 1 PINK: MSCLF
Slide 2: Legal Disclaimers
2 Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or perfor
Slide 3: Satellos: Restoring regeneration in muscle disorders
3 Satellos: Restoring regeneration in muscle disorders Scientific leaders Massive opportunity Muscle is a regenerative organ Experts in muscle stem cells and Span genetic disorders to ageing role in regeneration conditions to specialty markets Discovered polarity deficits Musculoskeletal dis
Slide 4: Satellos scientific founder: World leader in muscle stem cell research
4 Satellos scientific founder: World leader in muscle stem cell research Muscle stem cells Regeneration failure in Duchenne defined due to progenitor deficit 2000 2009 2013 2016 Dr. Michael Rudnicki Ottawa Hosp. Res. Inst. 2007 2012 2015 2019 Order of Canada Royal Society Fellow Canada Res. Ch
Slide 5: Seminal discoveries: Defining muscle stem cell driven cycle of regeneration
5 Seminal discoveries: Defining muscle stem cell driven cycle of regeneration I. Muscle stem cell III. Ageing (sarcopenia) Tendon Dividing stem cell (Pax7+/Myf5-) X Too few muscle stem cells Continuous track record of seminal discoveries in muscle stem cells and regeneration II. Balanced Regeneratio
Slide 6: Satellos Strategic Path
6 Focus initially on rare diseases SATELLOS Duchene and other dystrophies/atrophies Massive need, limited options and high value Strategic Path Compelling third-party evidence for Satellos approach Then broaden to mass market indications Ageing conditions (e.g., frailty/sarcopenia) Mus
Slide 7: Seminal discovery: Loss of polarity in Duchenne causes degeneration
7 Seminal discovery: Loss of polarity in Duchenne causes degeneration Healthy Polarity Regeneration Regeneration Duchenne Polarity Occurs Deficit 210-12 Progenitor (Differentiation) Stem cell Stem cell (Self-renewal) Stem cell Satellos is focused on restoring regeneration 7
Slide 8: Satellos approach: Correcting polarity to restore regeneration in Duchenne
8 Satellos approach: Correcting polarity to restore regeneration in Duchenne Regeneration restored Duchenne Corrected Progenitor Stem cell We are unique in focusing on regeneration to treat Duchenne 8
Slide 9: Duchenne muscular dystrophy: A failure of muscle regeneration throughout life
9 Duchenne muscular dystrophy: A failure of muscle regeneration throughout life Progressive muscle damage Current treatments don’t in Duchenne address regeneration Gene correction ~1 in 3,500 male births Dystrophin gene mutated Muscle Heart inflammation function Target existing fibers Muscle Ene
Slide 10: Our solution in Duchenne: Restoring stem cell driven muscle regeneration
10 Our solution in Duchenne: Restoring stem cell driven muscle regeneration Duchenne Satellos Solution Satellos Drug Persistent damage signal triggers stem cell divisions divisions to enable regeneration Stem cell dividing Stem cell dividing Satellos discovered an imbalance in stem cell divisions Su
Slide 11: Proof of Concept: Satellos treatment improves outcomes in Duchenne model
11 Proof of Concept (POC): Satellos treatment improves outcomes in Duchenne model Mdx Q: Can divisions be reset? Mouse Stem cells imbalanced X A: Yes, divisions can be reset Mdx Drug Mouse Stem cells in balance 11
Slide 12: Proof of Concept: Satellos treatment improves outcomes in Duchenne model
12 Proof of Concept (POC): Satellos treatment improves outcomes in Duchenne model Mdx Enhanced Muscle Quality Q: Can divisions be reset? Mouse Bigger muscle Stem cells imbalanced Less fibrosis (green) Larger fibers (black) X Untreated Treated Diaphragm Enhanced Muscle Performance A: Yes, divis
Slide 13: Third party evidence: Regeneration cited as modifier in dogs
13 Third party evidence: Regeneration cited as modifier in muscular dystrophy dogs Vieira et al, 2015 Jagged-1 Rescues Disease Dystrophy Phenotype Colony of dystrophin deficient dogs Some dogs had normal muscular function Mutation mapped to Jagged1 Precise MOA never fully determined by autho
Slide 14: Third party evidence: Nationwide researchers identify polarity as modifier
14 Third party evidence: Nationwide researchers identify polarity as potential disease modifier Some boys continue to walk more than 10 years longer than peers Analyzed 419 dystrophin null boys for factors associated with ambulation Mutation enhancing stem cell polarity (via PARD6G) identified a
Slide 15: Numerous Dystrophies may have polarity deficits
15 Dystrophin Associated Protein Complex Numerous Ullrich CMD & Collagen Dystrophies Bethlem Myopathy MDC1A may have Laminin LGMD2C-F polarity deficits α-Dystroglycanopathies α-DG Sarco α β у δ Sarcoglycan β-DG span complex • Mutations in DAPC result in Caveolin-3 muscular dystrophy LGMD1C • Satello
Slide 16: Near term priorities to build value in lead program
16 Near term priorities to build value in lead program 2022 Q1 Q2 Q3 Q4 Output: Multiple candidates suitable for Proof Design / advance drug candidates and file IP of Concept (POC) testing and optimization Evaluate / select lead drug candidates Pre-IND Studies Utility: Precedent in Duchenne for biom
Slide 17: Medium term value deliverables
17 Medium term value deliverables: Ph II trials in lead program and 2nd program clinic ready Q1/22 Q2/22 Q3/22 Q4/22 Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Lead Duchenne program in Phase II trials Delivered by Q2/24 Follow-on indication in Phase II trials Pre-IND studies completed, and Delivered by Q
Slide 18: Leadership
18 Leadership Frank Gleeson, MBA Michael Rudnicki, PhD, OC, FRS Sridhar Narayan, PhD, MBA Geoffrey Mackay Adam Mostafa William Jarosz, JD Board Member and CEO Chief Scientific Officer VP – Drug Discovery Chair — Board of Directors Board Member and Chair – Board Member and CEO – Audit Committee AmpB
Slide 19: Value potential is significant: Attractive market capitalizations in muscle space
19 Value potential is significant: Attractive market capitalizations in muscle space Phase 3 / Commercial 36 – 60 months US$2.5BN US$7.3BN US$0.6BN Phase 1 - 2 Trials 18 – 36 months US$0.1BN US$0.6BN US$0.4BN US$0.8BN Pre-IND/IND 12 – 18 months US$20M Development Stages Timeline Goals PEER COMPANIES
Slide 20: Cap Table and Key Professional Providers
20 SATELLOS (TSX: MSCL.V; PINK: MSCLF) Cap Table and Key Professional Providers KEY PROVIDERS CAPITAL TABLE Legal: Borden Ladner Gervais, LLP Common Shares 32,995,548 David Henry, LLB, Partner Warrants 2,162,762 Accounting: PricewaterhouseCoopers Stock options 2,847,252 Craig McMillan, CPA,
Slide 21: Summary
21 Transformative science in area of broad medical need Initial focus on rare, lethal disease ‒ Duchenne Summary Strong founding group and leadership team Huge potential upside on near term deliverables Plan for NASDAQ financing in 2022 Satellos Bioscience Inc. 65 Front Street East, Suite
Satellos Bioscience — Investor Presentation (February 2022) on 6ix